Description: Derma Sciences Inc.
Derma Sciences, Inc. engages in manufacturing, marketing, and selling wound care, wound closure and specialty securement devices, and skin care products. The company offers advanced/active wound care products comprising Medihoney dressings to manage non-chronic and hard-to-heal wounds, such as chronic ulcers, burns, and post-operative wounds; Bioguard dressings for prophylactic use to prevent hospital or community acquired infections through wound sites; Algicell Ag, an antimicrobial dressing; Xtrasorb dressings that convert fluid within the dressing to a gel and locks the exudates into the dressing; TCC-EZ, a dressing system for the management of diabetic foot ulcers; and occlusive dressings, such as hydrocolloids, foams, hydrogels, alginates, additional silver antimicrobial dressings, cleansers, and Dermagran products. It also provides traditional wound care products, such as gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages, and other compression devices, as well as adhesive bandages and related first aid products for the medical, industrial, private label, and retail markets. In addition, the company offers wound closure strips, nasal tube fasteners, and catheter fasteners to doctors, clinics, nursing homes, hospitals, and other institutions; and barrier creams and ointments, antibacterial cleansing foams and sprays, shampoos and body washes, hand sanitizers, bath additives, body oils, and moisturizers to nursing homes, hospitals, and home healthcare agencies. Further, it involves in developing DSC127, an angiotensin analog for use in wound healing and scar reduction. The company serves wound care centers, long-term care facilities, hospitals, home healthcare agencies, physiciansÂ’ offices, and closed door pharmacies. It sells its products primarily through independent distributors in the United States, Canada, and internationally. The company was founded in 1984 and is headquartered in Princeton, New Jersey.